Reported Earnings • May 28
First quarter 2026 earnings released: kr0.11 loss per share (vs kr0.27 loss in 1Q 2025) First quarter 2026 results: kr0.11 loss per share (improved from kr0.27 loss in 1Q 2025). Revenue: kr2.25m (down 14% from 1Q 2025). Net loss: kr2.37m (loss narrowed 41% from 1Q 2025). Revenue is forecast to grow 66% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings. Duyuru • May 18
AcouSort AB (publ), Annual General Meeting, Jun 18, 2026 AcouSort AB (publ), Annual General Meeting, Jun 18, 2026, at 09:00 W. Europe Standard Time. Location: medicon village (building 406), scheelevagen 14, in lund, lund Sweden Reported Earnings • Mar 02
Full year 2025 earnings released: kr0.64 loss per share (vs kr1.01 loss in FY 2024) Full year 2025 results: kr0.64 loss per share (improved from kr1.01 loss in FY 2024). Revenue: kr10.4m (up 4.0% from FY 2024). Net loss: kr12.2m (loss narrowed 19% from FY 2024). Revenue is forecast to grow 59% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings. New Risk • Jan 28
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr16m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 11% per year over the past 5 years. Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Market cap is less than US$10m (kr56.9m market cap, or US$6.44m). Minor Risk Revenue is less than US$5m (kr11m revenue, or US$1.2m). New Risk • Dec 19
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr16m free cash flow). Earnings have declined by 11% per year over the past 5 years. Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Market cap is less than US$10m (kr55.2m market cap, or US$5.96m). Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Revenue is less than US$5m (kr11m revenue, or US$1.2m). Reported Earnings • Nov 26
Third quarter 2025 earnings released: kr0.12 loss per share (vs kr0.25 loss in 3Q 2024) Third quarter 2025 results: kr0.12 loss per share (improved from kr0.25 loss in 3Q 2024). Revenue: kr2.11m (up 12% from 3Q 2024). Net loss: kr2.69m (loss narrowed 29% from 3Q 2024). Revenue is forecast to grow 70% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 27
Second quarter 2025 earnings released: kr0.14 loss per share (vs kr0.32 loss in 2Q 2024) Second quarter 2025 results: kr0.14 loss per share (improved from kr0.32 loss in 2Q 2024). Revenue: kr2.88m (up 44% from 2Q 2024). Net loss: kr2.82m (loss narrowed 40% from 2Q 2024). Revenue is forecast to grow 63% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 44% per year, which means it is performing significantly worse than earnings. Duyuru • Jun 25
AcouSort AB (publ) Approves Election of Stefan Blomsterberg and Per Sundkvist as New Board Members AcouSort AB (publ) at its AGM held on June 25, 2025, approved election of Stefan Blomsterberg and Per Sundkvist as new board members. Reported Earnings • May 30
First quarter 2025 earnings released: kr0.27 loss per share (vs kr0.25 loss in 1Q 2024) First quarter 2025 results: kr0.27 loss per share (further deteriorated from kr0.25 loss in 1Q 2024). Revenue: kr2.63m (down 12% from 1Q 2024). Net loss: kr4.02m (loss widened 7.9% from 1Q 2024). Revenue is forecast to grow 63% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 40% per year, which means it is performing significantly worse than earnings. Duyuru • May 23
AcouSort AB (publ), Annual General Meeting, Jun 25, 2025 AcouSort AB (publ), Annual General Meeting, Jun 25, 2025, at 09:00 W. Europe Standard Time. Location: at medicon village building 406, scheelevagen 14, lund Sweden New Risk • May 16
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 42% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 16% per year over the past 5 years. Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Market cap is less than US$10m (kr68.6m market cap, or US$7.02m). Minor Risk Revenue is less than US$5m (kr10m revenue, or US$1.0m). New Risk • May 06
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 42% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 16% per year over the past 5 years. Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Market cap is less than US$10m (kr80.4m market cap, or US$8.35m). Minor Risk Revenue is less than US$5m (kr10m revenue, or US$1.0m). Duyuru • May 06
AcouSort AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 24.919048 million. AcouSort AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 24.919048 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 6,229,762
Price\Range: SEK 4
Transaction Features: Rights Offering New Risk • Mar 06
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr20m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 16% per year over the past 5 years. Revenue is less than US$1m (kr10m revenue, or US$988k). Market cap is less than US$10m (kr55.4m market cap, or US$5.46m). New Risk • Feb 24
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: kr102.1m (US$9.59m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr19m free cash flow). Earnings have declined by 17% per year over the past 5 years. Revenue is less than US$1m (kr8.0m revenue, or US$754k). Market cap is less than US$10m (kr102.1m market cap, or US$9.59m). Minor Risk Share price has been volatile over the past 3 months (12% average weekly change). Board Change • Jan 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. Independent Board Member Katherine Flagg was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. New Risk • Dec 11
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr19m free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 17% per year over the past 5 years. Revenue is less than US$1m (kr8.0m revenue, or US$731k). Minor Risk Market cap is less than US$100m (kr176.2m market cap, or US$16.1m). Reported Earnings • Nov 28
Third quarter 2024 earnings released: kr0.25 loss per share (vs kr0.33 loss in 3Q 2023) Third quarter 2024 results: kr0.25 loss per share (improved from kr0.33 loss in 3Q 2023). Revenue: kr1.88m (down 13% from 3Q 2023). Net loss: kr3.81m (loss narrowed 12% from 3Q 2023). Revenue is forecast to grow 59% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 23% per year, which means it is performing significantly worse than earnings. Reported Earnings • Aug 29
Second quarter 2024 earnings released: kr0.32 loss per share (vs kr0.24 loss in 2Q 2023) Second quarter 2024 results: kr0.32 loss per share (further deteriorated from kr0.24 loss in 2Q 2023). Revenue: kr1.99m (down 41% from 2Q 2023). Net loss: kr4.71m (loss widened 48% from 2Q 2023). Revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 12% per year whereas the company’s share price has fallen by 13% per year. Reported Earnings • May 23
First quarter 2024 earnings released: kr0.25 loss per share (vs kr0.23 loss in 1Q 2023) First quarter 2024 results: kr0.25 loss per share (further deteriorated from kr0.23 loss in 1Q 2023). Revenue: kr2.97m (down 23% from 1Q 2023). Net loss: kr3.73m (loss widened 23% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 27% per year, which means it is performing significantly worse than earnings. Duyuru • May 03
AcouSort AB (publ) to Present Two Posters Highlighting the Value of Acoustofluidics Sample Preparation AcouSort AB (publ) will exhibit and present at CYTO 2024 - demonstrating the benefits of acoustic sample preparation for flow cytometry applications. CYTO 2024, the 37th annual Congress of the International Society for the Advancement of Cytometry is an international conference on the many facets of cytometry science and engineering. In line with the company's focus on novel opportunities within cytometry, AcouSort will participate in the conference to present its innovative solutions for sample preparation and the vital role they can play to improve flow cytometry outcomes. AcouSort has also been selected to present two posters highlighting the value of acoustofluidics sample preparation. The first poster is presented by Dr Vera A Tang of University of Ottawa. During the spring of 2024, AcouSort has collaborated with Dr Tang and her team on the development of a new method for isolation of cells from dissociation tissue using the AcouWash. The poster describes how the AcouWash system is used to purify dissociation tissue samples and efficiently remove debris and dead cells from the target cells, something that is very difficult to do with other techniques. Dr Tang's main conclusions are that sample preparation using the AcouWash system offers a low-cost, gentle, and effective way to ensure that downstream analysis is performed on high quality viable samples. The second poster presents AcouSort's in-house work on high throughput cell wash and show new data on efficient and gentle cell wash at flowrates up to 5 mL/minute combined with a 5x up-concentration. By using acoustic cell wash, contaminants can be efficiently removed from the cells in a one-step process while retaining more than 98% of the cells. Proliferation studies also show that the AcouWash technology is very gentle to the cells and that cell proliferation after acoustic processing is the same as for unprocessed samples. The results presented in the poster is a great example on how acoustic sorting can be rapid, efficient, and gentle to the cells, combining several sample preparation steps into one. Reported Earnings • Apr 02
Full year 2023 earnings released: kr1.29 loss per share (vs kr1.04 loss in FY 2022) Full year 2023 results: kr1.29 loss per share (further deteriorated from kr1.04 loss in FY 2022). Revenue: kr10.6m (up 23% from FY 2022). Net loss: kr17.1m (loss widened 24% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has fallen by 26% per year, which means it is performing significantly worse than earnings. New Risk • Mar 29
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr13m free cash flow). Earnings have declined by 13% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Shareholders have been diluted in the past year (13% increase in shares outstanding). Revenue is less than US$5m (kr12m revenue, or US$1.1m). Market cap is less than US$100m (kr183.3m market cap, or US$17.1m). Recent Insider Transactions • Mar 04
Founder & Independent Director recently bought kr52k worth of stock On the 1st of March, Stefan Scheding bought around 4k shares on-market at roughly kr12.66 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Stefan's only on-market trade for the last 12 months. New Risk • Dec 03
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 12% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr13m free cash flow). Earnings have declined by 13% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (12% increase in shares outstanding). Revenue is less than US$5m (kr12m revenue, or US$1.2m). Market cap is less than US$100m (kr228.6m market cap, or US$22.0m). Duyuru • Dec 02
AcouSort AB (publ) has completed a Composite Units Offering. AcouSort AB (publ) has completed a Composite Units Offering.
Security Name: Units
Security Type: Equity/Derivative Unit
Securities Offered: 515,526
Price\Range: SEK 45
Transaction Features: Rights Offering Reported Earnings • Nov 08
Third quarter 2023 earnings released: kr0.33 loss per share (vs kr0.32 loss in 3Q 2022) Third quarter 2023 results: kr0.33 loss per share (further deteriorated from kr0.32 loss in 3Q 2022). Revenue: kr2.16m (up 63% from 3Q 2022). Net loss: kr4.30m (loss widened 2.0% from 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings. New Risk • Nov 07
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr12m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 13% per year over the past 5 years. Minor Risks Revenue is less than US$5m (kr11m revenue, or US$1.0m). Market cap is less than US$100m (kr211.2m market cap, or US$19.3m). Duyuru • Nov 07
AcouSort AB (publ) to Report Q4, 2023 Results on Feb 28, 2024 AcouSort AB (publ) announced that they will report Q4, 2023 results on Feb 28, 2024 New Risk • Aug 25
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr12m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr12m free cash flow). Earnings have declined by 13% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Revenue is less than US$5m (kr11m revenue, or US$1.0m). Market cap is less than US$100m (kr235.0m market cap, or US$21.2m). New Risk • Aug 15
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 13% per year over the past 5 years. Revenue is less than US$1m (kr9.7m revenue, or US$899k). Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Market cap is less than US$100m (kr231.0m market cap, or US$21.3m). Duyuru • Jun 17
AcouSort AB (publ) Recruits Henrik Johansson to the Position as Director of Research and Technology AcouSort AB (publ) has recruited Henrik Johansson to the position as Director of Research and Technology. Henrik has significant experience from startup environment within the biotech space as well as from R&D management roles at Agilent and PerkinElmer. Going forward, he will play a key role in the further development of the company's technology portfolio. As Director of Research and Technology, Henrik will be responsible for the company's Research projects. Primary focus will be on managing research activities aimed at further developing and applying the company's core technology to address unmet needs identified in clinical research and practice. Henrik will also be responsible for identifying new technology frontiers that enables development of products. Henrik has extensive knowledge of developing novel products based on proprietary technology and experience of leading product development projects from idea stage to product launch. Reported Earnings • Jun 01
First quarter 2023 earnings released: kr0.23 loss per share (vs kr0.20 loss in 1Q 2022) First quarter 2023 results: kr0.23 loss per share (further deteriorated from kr0.20 loss in 1Q 2022). Revenue: kr3.85m (up 43% from 1Q 2022). Net loss: kr3.04m (loss widened 16% from 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings. Duyuru • May 23
AcouSort AB (publ) Launches Next Generation AcouTrap at CYTO 2023 AcouSort launches next generation AcouTrap at CYTO 2023. CYTO is organized by the International Society for the Advancement of Cytometry and attended by leading researchers and instrumentation providers within flow cytometry. This year, AcouSort will use the conference to launch the new and much improved AcouTrap system. The conference is held in Montréal, Canada, May 20-24. The new AcouTrap 3 system comes with improved design and an updated and intuitive software graphical user interface (GUI), which simplifies user workflows. The new design and new software are based on customer feedback from AcouSort's last generation of AcouTrap. Along with the upgrades to the AcouTrap system, AcouSort also presents two new trapping units with improved performance. The smaller unit has a capacity of up to 100,000 cells and is d esigned for minute samples and rare cells, while the enhanced unit has higher throughput and can handle up to 0.5 million cells. Both units allow for gentle, automated handling with minimal cell loss . Reported Earnings • Feb 22
Full year 2022 earnings released: kr0.98 loss per share (vs kr0.92 loss in FY 2021) Full year 2022 results: kr0.98 loss per share (further deteriorated from kr0.92 loss in FY 2021). Revenue: kr8.59m (up 44% from FY 2021). Net loss: kr12.9m (loss widened 5.8% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings. Recent Insider Transactions • Dec 06
Founder & Independent Director recently bought kr68k worth of stock On the 2nd of December, Thomas Laurell bought around 4k shares on-market at roughly kr19.33 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Thomas' only on-market trade for the last 12 months. Reported Earnings • Nov 24
Third quarter 2022 earnings released: kr0.32 loss per share (vs kr0.30 loss in 3Q 2021) Third quarter 2022 results: kr0.32 loss per share (further deteriorated from kr0.30 loss in 3Q 2021). Revenue: kr1.33m (up 79% from 3Q 2021). Net loss: kr4.22m (loss widened 22% from 3Q 2021). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 29% per year, which means it is well ahead of earnings. Reported Earnings • Aug 24
Second quarter 2022 earnings released: kr0.31 loss per share (vs kr0.31 loss in 2Q 2021) Second quarter 2022 results: kr0.31 loss per share (vs kr0.31 loss in 2Q 2021). Revenue: kr1.81m (up 51% from 2Q 2021). Net loss: kr4.03m (loss widened 16% from 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 21% per year, which means it is well ahead of earnings. Reported Earnings • May 19
First quarter 2022 earnings released: kr0.20 loss per share (vs kr0.15 loss in 1Q 2021) First quarter 2022 results: kr0.20 loss per share (down from kr0.15 loss in 1Q 2021). Revenue: kr2.69m (down 4.1% from 1Q 2021). Net loss: kr2.61m (loss widened 55% from 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 25% per year, which means it is well ahead of earnings. Recent Insider Transactions • Mar 05
Founder & Independent Director recently bought kr95k worth of stock On the 3rd of March, Stefan Scheding bought around 5k shares on-market at roughly kr19.00 per share. This was the largest purchase by an insider in the last 3 months. Stefan has been a buyer over the last 12 months, purchasing a net total of kr120k worth in shares. Reported Earnings • Feb 25
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: kr0.92 loss per share (down from kr0.70 loss in FY 2020). Revenue: kr5.96m (up 21% from FY 2020). Net loss: kr12.2m (loss widened 53% from FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has increased by 36% per year, which means it is well ahead of earnings. Reported Earnings • Nov 25
Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations Third quarter 2021 results: kr0.31 loss per share (down from kr0.20 loss in 3Q 2020). Revenue: kr739.0k (up 262% from 3Q 2020). Net loss: kr3.45m (loss widened 56% from 3Q 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 44% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Aug 26
Second quarter 2021 earnings released: kr0.31 loss per share (vs kr0.12 loss in 2Q 2020) The company reported a poor second quarter result with increased losses, weaker revenues and weaker control over costs. Second quarter 2021 results: Revenue: kr1.20m (down 17% from 2Q 2020). Net loss: kr3.48m (loss widened 160% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 36% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • May 28
First quarter 2021 earnings released: kr0.15 loss per share (vs kr0.10 loss in 1Q 2020) The company reported a mediocre first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: kr2.80m (up 34% from 1Q 2020). Net loss: kr1.69m (loss widened 65% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Feb 25
Full year 2020 earnings released: kr0.70 loss per share (vs kr0.96 loss in FY 2019) The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: kr6.82m (up 268% from FY 2019). Net loss: kr7.98m (loss narrowed 17% from FY 2019). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 23% per year, which means it is tracking significantly ahead of earnings growth. Duyuru • Jan 29
AcouSort AB Enters Collaboration Agreement with Belgian Diagnostics Company AcouSort AB has entered a partnership with a Belgian diagnostics company that develops innovative products for point-of-care testing. Together, the companies will develop a test platform based on AcouSort's technology to be used in the Belgian company's product development. The Belgium-based company is developing a platform for point-of-care diagnostics based on whole blood, initially focusing on analysis of blood cells. In the long term, there are plans to develop the system to be able to analyze other fractions of blood samples. With the jointly developed test platform, the Belgian company will evaluate if AcouSort's technology for integrated blood separation can improve their system's measurement performance. Duyuru • Jan 17
Physio-Tech Co.,Ltd. acquired AcouTrap system from AcouSort AB (publ) (OM:ACOU). Physio-Tech Co.,Ltd. acquired AcouTrap system from AcouSort AB (publ) (OM:ACOU) on January 15, 2021.
Physio-Tech Co.,Ltd. completed the acquisition of AcouTrap system from AcouSort AB (publ) (OM:ACOU) on January 15, 2021. Is New 90 Day High Low • Jan 14
New 90-day high: kr26.90 The company is up 76% from its price of kr15.25 on 15 October 2020. The Swedish market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 4.0% over the same period. Is New 90 Day High Low • Dec 28
New 90-day high: kr22.30 The company is up 63% from its price of kr13.70 on 29 September 2020. The Swedish market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 12% over the same period. Is New 90 Day High Low • Dec 04
New 90-day high: kr21.80 The company is up 124% from its price of kr9.74 on 04 September 2020. The Swedish market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 1.0% over the same period. Reported Earnings • Nov 28
Third quarter 2020 earnings released: kr0.20 loss per share The company reported a soft third quarter result with increased losses and weaker control over expenses, although revenues were improved. Third quarter 2020 results: Revenue: kr662.0k (up 25% from 3Q 2019). Net loss: kr2.21m (loss widened 27% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 25% per year, which means it is tracking significantly ahead of earnings growth. Is New 90 Day High Low • Nov 11
New 90-day high: kr19.25 The company is up 102% from its price of kr9.52 on 13 August 2020. The Swedish market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 9.0% over the same period. Is New 90 Day High Low • Oct 07
New 90-day high: kr16.85 The company is up 63% from its price of kr10.35 on 09 July 2020. The Swedish market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 7.0% over the same period. Is New 90 Day High Low • Sep 22
New 90-day high: kr12.40 The company is up 22% from its price of kr10.15 on 24 June 2020. The Swedish market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 19% over the same period. 